Results 51 to 60 of about 344,680 (247)
Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma
Anti-CD38 monoclonal antibodies like Daratumumab (Dara) are effective in multiple myeloma (MM); however, drug resistance ultimately occurs and the mechanisms behind this are poorly understood.
Jiye Liu +21 more
doaj +1 more source
High-Order Fiber Mode Beam Parameter Optimization for Transport and Rotation of Single Cells
Optical tweezers are becoming increasingly important in biomedical applications for the trapping, propelling, binding, and controlled rotation of biological particles.
Zihao Shan +7 more
doaj +1 more source
Extramedullary Plasmacytoma of Soft Tissues and Gingiva [PDF]
Extramedullary plasmacytoma (EMP) is a rare plasma cell neoplasm of soft tissue without bone marrow involvement or other systemic characteristics of multiple myeloma. It accounts for 3% of all plasma cell tumors.
Jena, M, Kaler, AK, Shankar, A
core
Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells. [PDF]
The HOX genes encode a family of transcription factors that are dysregulated in several malignancies and have been implicated in oncogenesis and cancer cell survival.
Daniels, TR +5 more
core +1 more source
The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM ...
Shih-Feng Cho +7 more
doaj +1 more source
A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways.
Shaji Kumar +15 more
doaj +1 more source
The non-coding RNA landscape of plasma cell dyscrasias [PDF]
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A +3 more
core +1 more source
Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s ...
Maroun Bou Zerdan +4 more
doaj +1 more source
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress.
Keiji Kurata +28 more
doaj +1 more source
JNK signalling in cancer: In need of new, smarter therapeutic targets [PDF]
Copyright © 2013 The British Pharmacological Society. This is the accepted version of the following article: Bubici, C. and Papa, S. (2014), JNK signalling in cancer: in need of new, smarter therapeutic targets.
Adams +137 more
core +2 more sources

